Company Overview of OvaScience, Inc.
OvaScience, Inc., a life sciences company, is engaged in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. It is developing potential next generation in vitro fertilization (IVF) technologies through applying proprietary technology to identify and purify EggPCs. The company has two product candidates in development: OvaTure to create mature fertilizable eggs from a woman’s own EggPCs without the need for hormone injections; and AUGMENT to improve egg quality and increase the success of IVF. The company was formerly known as Ovastem, I...
215 First Street
Cambridge, MA 02142
Founded in 2011
Key Executives for OvaScience, Inc.
Principal Financial Officer
Total Annual Compensation: $310.0K
Compensation as of Fiscal Year 2012.
OvaScience, Inc. Key Developments
OvaScience, Inc. and Intrexon Corporation Establish OvaXon, LLC
Dec 19 13
OvaScience, Inc. and Intrexon Corporation formed OvaXon, LLC to conduct the joint venture. Each party contributed $1.5 million to OvaXon and each has a 50% equity interest, and research and development costs and profits to be split accordingly. OvaXon will be governed by a board of managers, which initially will have equal representation by OvaScience and Intrexon. Pursuant to an Intellectual Property License between OvaScience and OvaXon, OvaScience licensed its technology in the field of the joint venture to OvaXon, and OvaXon entered into a collaboration agreement with Intrexon to develop the OvaScience technology in the field utilizing Intrexon's synthetic biology platform.
OvaScience, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 09:00 AM
Nov 15 13
OvaScience, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 09:00 AM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States. Speakers: Michelle Dipp, Co-Founder, Chief Executive Officer, President and Director.
Ovascience, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013
Nov 13 13
OvaScience, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported net loss applicable to common stockholders of $6,891,000 or $0.40 per basic and diluted share as compared to $3,118,000, or $0.42 per basic and diluted share a year ago. Loss from operations was $6,925,000 against $3,120,000 a year ago. The increase was primarily due to higher personnel costs including stock-based compensation expense due to significant organizational growth and augment development expenses.
For the nine months, the company reported net loss applicable to common stockholders of $18,044,000 or $1.14 per basic and diluted share as compared to $3,918,000, or $2.69 per basic and diluted share a year ago. Loss from operations was $18,121,000 against $9,320,000 a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 12, 2013